Division of Clinical Neuroscience

Top > Division of Clinical Neuroscience

Publication

2012年

  1. Fujita Y, Kunitachi S, Iyo M, Hashimoto K: Antibiotic drug minocycline prevents methamphetamine-rewarding effects in mice. Pharmacol. Biochem. Behav. 2012; In press. [Pubmed]
  2. Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, Hashimoto K: Protective effects of antioxidant sulforaphane on the behavioral changes and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology 2012; in press. [PubMed]
  3. Hashimoto K: A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin. Psychopharmacol. Neurosci. 2012; In press.
  4. Kishimoto A, Kaneko M, Gotoh T, Hashimoto K: Ifenprodil for the treatment of flashbacks in female Posttraumatic Stress Disorder patients with a history of childhood sexual abuse. Biol. Psychiatry 2012; in press. [PubMed]
  5. Hashimoto K, Furuse, T: Sigma-1 receptor agonist fluvoxamine for delirium in elderly adults. Int. J. Geriatr. Psychiatry 2012; in press. [PubMed]
  6. Niitsu T, Iyo M, Hashimoto K: Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease. Curr. Pharm. Des. 2012; In press. [Pubmed]
  7. Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M: Chronic treatment with aripiprazole, a dopamine D2 receptor partial agonist, stabilizes dopamine sensitivity in rats. Schizophrenia Bull. 2012; In press. [PubMed]
  8. Tokita K, Yamaji T, Hashimoto K: Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 2012 February; 100 (4): 688-704. [PubMed]
  9. Arakawa S, Shirayama Y, Fujita Y, Ishima T, Horio M, Muneoka K, Iyo M, Hashimoto K: Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol. Biochem. Behav. 2012 Jan; 100 (3): 601-606. [PubMed]

2011年

  1. Ishikawa M, Sakata M, Toyohara J, Oda K, Ishii K, Wu J, Yoshida Y, Iyo M, Ishiwata K, Hashimoto K: Occupancy of α7 nicotinic acetylcholine receptors in the brain by tropisetron: A PET study using [11C]CHIBA-1001 in healthy human subjects. Clin. Psychopharmacol. Neurosci. 2011; Dec; 9 (3): 111-116.
  2. Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Fukami G, Fujisaki M, Watanabe H, Nakazato M, Asano M, Kimura S, Hashimoto K, Iyo M: Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011l2011 Dec 1; 35 (8): 1836-1840. [PubMed]
  3. Shinmura C, Suda S, Tsuchiya KJ, Hashimoto K, Ohno K, Matsuzaki H, Iwata K, Matsumoto K, Wakuda T, Kameno Y, Suzuki K, Tsujii M, Nakamura K, Takei N, Mori N: Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS ONE 2011 October; 6 (10): e25340. [PubMed]
  4. Kobayakawa M, Inagaki M, Fujimori M, Hamazaki K, Hamazaki T, Akechi T, Tsugane S, Nishiwaki Y, Goto K, Hashimoto K, Yamawaki S, Uchitomi Y: Serum brain-derived neurotrophic factor and antidepressant-naïve major depression after lung cancer diagonosis. Jap. J. Clin. Oncol. 2011 Oct; 41 (10): 1233-1237. [PubMed]
  5. Tadokoro S, Kanahara N, Kikuchi S, Hashimoto K, Iyo M: Fluvoxamine prevents onseto of psychosis: a case report of a patient at ultra-high risk of psychotic disorder. Ann. Gen. Psychiatry 2011 Sep 30; 10 (1): 26. [PubMed]
  6. Sasaki T, Niitsu T, Hashimoto T, Kanahara N, Shiina A, Hasegawa T, Kimura H, Ishikawa M, Tone J, Yamauchi A, Hosoda Y, Kunou M, Takahashi J, Ishima T, Fujita Y, Nakazato M, Hashimoto K, Iyo M: Decreased levels of brain-derived neurotrophic factor in male pediatric patients with depression. Open Clin. Chem. J. 2011 September 30; 4: 28-33.
  7. Shirayama Y, Muneoka K, Fukumoto M, Tadokoro S, Hashimoto K, Iyo M: Infusions of allopregnanolone into the hippocampus and amygdala, but not into nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus 2011 Oct; 21 (10): 1105-1113.[PubMed]
  8. Horio M, Kohno M, Fujita Y, Ishima T, Inoue R, Mori H, Hashimoto K: Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice. Neurochem. Int. 2011 November; 59: 853-859.
  9. Shirayama Y, Konishi T, Hashimoto K: Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial J. Clin. Psychopharmacol. 2011 Oct. 1; 31 (5): 659-661. [PubMed]
  10. Matsuzawa D, Hashimoto K: MRS study of antioxidant defense system in schizophrenia. Antioxi. Redox Sig. 2011 Oct 1; 15 (7): 2057-2065. [PubMed]
  11. Hashimoto K: The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011 August 15; 35 (7): 1558-1568.[PubMed]
  12. Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hamazaki T, Hashimoto K: Potential role of BDNF in omega-3 fatty acid supplementation to prevent posttraumatic distress after accidental injury: An open-labeled pilot study. Psychother. Psychosom. 2011 June 30; 80 (5): 310-312.[PubMed]
  13. Zhang J, Wu J, Toyohara J, Fujita Y, Chen H, Hashimoto K. Pharmacological characterization of [3H]CHIBA-3007 binding to glycine transporter 1 in the rat brain. PLoS ONE 2011; 2011 June 23; 6 (6): e21322. [PubMed]
  14. Ma XC, Jiang D, Jiang WH, Wang F, Jia M, Wu J, Hashimoto K, Dang JH, Gao CG: Social isolation-induced aggression potentiates anxiety and depressive-like behaviors in male mice subjected to unpredictable chronic mild stress. PLoS One 2011 Jun 17; 6 (6): e20955. [PubMed]
  15. Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S, Lin C, Yoshida S, Ishikawa M, Higuchi Y, Seo T, Ueoka Y, Tomotake M, Keneda Y, Darby D, Maruff P, Iyo M, Kasai K, Higuchi T, Sumiyoshi T, Ohmori T, Takahashi K, Hashimoto K: Criterion and constract validity of the Cogstate Schizophrenia Battery in Japanese patients with schizophrenia. PLoS ONE 2011 May 26; 6 (5), e20469.[PubMed]
  16. Toyohara J, Ishiwata K, Sakata M, Wu J, Nishiyama S, Tsukada H, Hashimoto K: In vivo evaluation of cabon-11 labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. Nuc. Med. Biol. 2011 May; 38 (4): 517-527. [PubMed]
  17. Hashimoto K: Can minocycline prevent the onset of Alzheimer’s disease? Ann. Neurol. 2011; 2011 April; 69 (4): 739. [PubMed]
  18. Sakata M, Wu J, Toyohara J, Oda K, Ishikawa M, Ishii K, Hashimoto K, Ishiwata K: Biodistribution and radiation dosimetry of the α7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in human. Nuc. Med. Biol. 2011 April; 38 (3): 443-448. [PubMed]
  19. Zhang L, Yokoi F, Jin YH, DeAndrade MP, Hashimoto K, Standaert DG, Li Y: Altered dendritic morphology of Purkinje cells in Dyt1 △GAG knock-in and Purkinje-cell specific Dyt1 conditional knockout mice. PLoS ONE 2011 March 29; 6(3): e18357.[PubMed]
  20. Ishikawa M, Hashimoto K: Alpha-7 nicotinic receptor: a potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011 March; 17 (2): 121-129. [PubMed]
  21. Hashimoto K: Glycine transportor-1: a potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011 March; 17 (2): 112-120. [PubMed]
  22. Hashimoto K: Novel potential therapeutic approaches for schizophrenia. Curr. Pharm. Des. 2011 March; 17 (2): 92-93. [PubMed]
  23. Hashimoto K, Ishima T: Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol. PLoS ONE 2011 March 1; 6 (3): e17431.[PubMed]
  24. Itoh K, Ishima T, Kehler J, Hashimoto K: Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma and IP3 receptors. Brain Res. 2011; March 4; 1377: 32-40.[PubMed]
  25. Ozeki Y, Pickard BS, Kano SI, Malloy MP, Zeledon M, Sun DQ, Fujii K, Wakui K, Shirayama Y, Fukushima Y, Kunugi H, Hashimoto K, Muir WJ, Blackwood DH, Sawa A: A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypical personality disorder: altered L-serine level associated with disruption of PSAT1 gene expression. Neurosci. Res. 2011 Feb; 69 (2): 154-160. [PubMed]
  26. Takatsu Y, Fujita Y, Tsukamoto T, Slusher B, Hashimoto K: Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits. Brain Res. 2011 Jan; 1371: 82-86. [PubMed]
  27. Sofuoglu M, Mooney M, Kosten TR, Walters A, Hashimoto K: Minocycline attenuates subjective-rewarding effects of dextroamphetamine in humans. Psychopharmacol. 2011 Jan 31; 213 (1): 61-68. [PubMed]
  28. Hashimoto K: Role of mTOR signaling pathway in the rapid antidepressant action of ketamine. Exp. Rev. Neurotherapeu. 2011 Jan; 11 (1): 33-36. [PubMed]
  29. Gong N, Gao ZY, Huang JL, Wang YC, Hashimoto K, Wang YX: A series of DAO inhibitors specifically prevents and reverses formalin-induced tonic pain in rats. J. Pharmacol. Exp. Ther. 2011 Jan; 336 (1): 282-293. [PubMed]
  30. Zhang L, Haraguchi S, Koda T, Hashimoto K, Nakagawara A: Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice. J. Biomed. Biotech. 2011; 2011: 831092. [PubMed]
  31. 橋本謙二(2011)特集 統合失調症の社会復帰-QOLの向上を目指したバイオ・ソーシャルな取り組み.統合失調症の病態からみた新しい治療薬の開発. 精神神経学雑誌. 113 (4): 368-372.
  32. 吉田泰介、伊豫雅臣、橋本謙二(2011)薬物療法による予後改善:認知改善薬を中心に. 精神医学 53: 127-134.
  33. 谷渕由布子、伊豫雅臣、橋本謙二(2011)薬物依存症の末梢血バイオマーカーに関する最新知見:神経栄養因子およびサイトカインを中心に. 日本アルコール・薬物医学会雑誌 45: 515-524.
  34. 橋本謙二、平田幸一、加藤忠史(2011)うつ病関連疾患(PSD, 双極性障害)をめぐる最近の話題-シグマ-1受容体アゴニストの可能性を探る.臨床精神薬理 14: 303-318.
  35. 橋本謙二、岸本 朗、白山幸彦、古瀬 勉(2011)精神病性うつ病に対するシグマ-1受容体アゴニストフルボキサミン単剤治療の可能性.新薬と臨床 60: 34-43.
  36. 橋本謙二(2011)統合失調症治療薬の新たな開発の動向. 医薬ジャーナル 47: 111-115.
  37. 橋本謙二(2011)うつ・不安障害治療フォーラム.講演1:Fluvoxamineの特徴-シグマ-1受容体アゴニスト作用-. 臨床精神薬理 14: 129-140.

2010年

  1. Chen H, Wu J, Zhang J, Hashimoto K: Recent topics on pharmacotherapy for amphetamine-like stimulants abuse and dependence. Curr. Drug Abuse Rev. 2010 Dec. 1; 3 (4): 222-238. [PubMed]
  2. Wu J, Ishikawa M, Zhang J, Hashimoto K: Brain imaging of nicotinic receptors in Alzheimer’s disease. Int. J. Alzheimer’s Dis. 2010; 2010: ID548913. [PubMed]
  3. Tanibuchi Y, Fujita Y, Horio M, Iyo M, Hashimoto K: Effects of quetiapine on prepulse inhibition deficits in mice after administration of dizocilpine: a possible role of adrenergic α1 receptors. Clin. Psychopharmacol. Neurosci. 2010 Dec.; 8 (3): 133-136.
  4. Maekawa T, Ohnishi T, Hashimoto K, Watanabe A, Iwayama Y, Ohba H, Hattori E, Yamada K, and Yoshikawa T. Analyses of mechanism for mouse strain-dependent prepulse inhibition point to a role of Shmt1(SHMT1)in mice and schizophrenia. J. Neurochem. 2010 Dec.; 115 (6): 1374-1385. [PubMed]
  5. Hashimoto K, Ishima T. A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiator factor eIF4AI. PLoS One 2010 Nov. 8; 5 (11): e15430. [PubMed]
  6. Minase T, Ishima T, Itoh K, Hashimoto K. Potentaition of nerve growth factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: a potential role of IP3 receptors. Eur. J. Pharmacol. 2010 Dec. 1; 648 (1-3): 67-73. [PubMed]
  7. Wu J, Toyohara J, Tanibuchi Y, Fujita Y, Zhang J, Chen H, Matsuo M, Wang RF, Hashimoto K. Characterization of [125I]CHIBA-1006 binding to α7 nicotinic acetylcholine receptors in rat brain. Brain Res. 2010 Nov. 11; 1360: 130-137. [PubMed]
  8. Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M. Fluvoxamine improved negative symptoms and cognitive impairments in a patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010 Oct 1; 34(7): 1345-1346.[PubMed]
  9. Tanibuchi Y, Shimagami M, Fukami G, Sekine Y, Iyo M, Hashimoto K. A case of methamphetamine use disorder treated with the antibiotic drug minocycline. Gen. Hospital Psychiatry. 2010; Sept.-Oct.; 32(5):559.el-559.e3. [PubMed]
  10. Toyohara J, Wu J, Hashimoto K. Recent development of radioligands for imaging α7 nicotinic acetylcholine receptors in the brain. Curr. Top. Med. Chem. 2010; 10(15): 1544-1557.[PubMed]
  11. Hashimoto K. Neurosteroid pregnenolone and sigma-1 receptor function. Clin. Psychopharmacol. Neurosci. 2010 August; 8(2): 115.
  12. Hashimoto K, Fujita Y, Ishima T, Horio M, Hagiwara H, Tanibuchi Y, Iyo M. Effects of cilostazol on dizocilpine-induced hyperlocomotion and prepulse inhibition deficits in mice. Clin. Psychopharmacol. Neurosci. 2010 August; 8(2): 74-78.
  13. Tanibuchi Y, Wu J, Toyohara J, Fujita Y, Iyo M, Hashimoto K. Characterization of [3H]CHIBA-1001 binding to α7 nicotinic acetylcholine receptors in the brain from rat, monkey, and human. Brain Res. 2010 Aug. 12; 1348: 200-208. [PubMed]
  14. Hashimoto K. Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010 Aug. 16; 34(6): 1132 [PubMed]
  15. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci. 2010 Aug; 64 (4): 341-357. [PubMed]
  16. Nakazato M, Hashimoto K, Schmidt U, Tchanturia K, Campbell IC, Collier DA, Iyo M, Treasure J. Serum glutamine, set shifting ability and anorexia nervosa. Ann. Gen. Psychiatry 2010 June 25; 9 (1): 29. [PubMed]
  17. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for postoperative delirium: report of 3 cases. Ann. Gen. Psychiatry 2010 June 24; 9: 28. [PubMed]
  18. Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, Haraguchi T, Kanahara N, Shiraishi T, Fujisaki M, Fukami G, Nakazato M, Iyo M, Hashimoto K. A randomized, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann. Gen. Psychiatry 2010 June 24; 9: 27. [PubMed]
  19. Hashimoto K. Comments to “The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia”. J. Psychopharmacol.2010 Jul.; 24 (7): 1133-1134. [PubMed]
  20. Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A, Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, Itokawa M. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch. Gen. Psychiatry 2010 June; 67 (6): 589-597. [PubMed]
  21. Toyohara J, Hashimoto K. α7 Nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer’s disease. Open Med. Chem. J. 2010;4: 37-56. [PubMed]
  22. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med. Chem. J. 2010; 4: 10-19. [PubMed]
  23. Hashimoto K. Editorial: Novel therapeutic drugs for neuropsychiatric disorders. Open Med. Chem. J. 2010; 4: 1-2. [PubMed]
  24. Kishimoto A, Todani A, Miura J, Kitagaki T, Hashimoto K. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report. Ann. Gen. Psychiatry 2010 May 21; 9 (1): 23. [PubMed]
  25. Shirayama Y, Hashimoto K. A case of psychotic depression treated with fluvoxamine monotherapy. Clin. Psychopharmacol. Neurosci. 2010 April; 8 (1): 53-54.
  26. Hashimoto K, Fujita Y, Ishima T, Horio M, Hagiwara H, Tanibuchi Y, Iyo M. Effects of cilostazol on cognitive deficits in mice after repeated administration of phencyclidine. Clin. Psychopharmacol. Neurosci. 2010 April; 8 (1): 26-29.
  27. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of 5 cases. Ann. Gen. Psychiatry 2010 April 24; 9:18. [PubMed]
  28. Furuse T, Hashimoto K. Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of 5 cases. Ann. Gen. Psychiatry2010 April 24; 9:17. [PubMed]
  29. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacol. - Clin. Exp. 2010 April; 25 (3): 193-200. [PubMed]
  30. Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hashimoto K, Hamazaki T. Omega-3 fatty acids for the secondary prevention of posttraumatic stress disorder following an accidential injury: An open-label pilot study. J. Clin. Psychopharmacol. 2010 April; 30 (2): 217-219. [PubMed]
  31. Furuse T, Hashimoto K. Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. Ann. Gen. Psychiatry 2010 Mar 6; 9: 11. [PubMed]
  32. Iwayama Y, Hattori E, Maekawa M, Yamada K, Toyota T, Ohnishi T, Iwata Y, Tsuchiya KJ, Sugihara G, Kikuchi M, Hashimoto K, Iyo M, Inada T, Kunugi H, Ozaki N, Iwata N, Nanko S, Iwamoto K, Okazaki Y, Kato T, Yoshikawa T. Association analyses between brain-expressed fatty-acid binding protein (FABP) genes and schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010 Mar 5; 153B: 484-493. [PubMed]
  33. Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K, Kohno M, Hashimoto K, Iyo M, Shimizu E. Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci. Lett. 2010 Feb 26; 471 (1): 53-57. [PubMed]
  34. Suzuki K, Okada K, Wakuda T, Shinmura C, Kameno Y, Iwata K, Takahashi T, Suda S, Matsuzaki H, Iwata Y, Hashimoto K, Mori N. Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine. PLOS ONE. 2010 Feb 17; 5 (2): e9260. [PubMed]
  35. Ishii D, Matsuzawa D, Fujita Y, Sutoh C, Ohtsuka H, Matsuda S, Kanahara N, Hashimoto K, Iyo M, Shimizu E. Enhancement of acoustic prepulse inhibition by contextual fear conditioning in mice is maintained even after contextual fear extinction. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 Feb 1; 34 (1): 183-188. [PubMed]
  36. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer’s disease. Ann. Gen. Psychiatry. 2010 Jan 20; 9: 6. [PubMed]
  37. Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E, Ikehira H, Hashimoto K, Iyo M. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study. Neuroimage. 2010 Feb 1; 49(3): 2783-2790. [PubMed]
  38. Toyohara J, Ishiwata K, Sakata M, Wu J, Nishiyama S, Tsukada H, Hashimoto K. In vivo evaluation of α7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys. PLOS ONE. 2010 Feb 1; 5 (2): e8961. [PubMed]
  39. Okamura N, Reinscheid R, Ohgake S, Iyo M, Hashimoto K. Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801. Neuropharmacology. 2010 Jan; 58 (1): 166-172. [PubMed]
  40. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J. Receptor Ligand Channel Res. 2010; 3: 25-36. [PDF]
  41. 白山幸彦、橋本謙二(2010)フルボキサミン単剤療法で治療した精神病性うつ病の1例.新薬と臨床 59, 2364-2366.
  42. 吉川武男、前川素子、大西哲生、橋本謙二、渡邉明子(2010)統合失調症グルタミン酸仮説におけるSHMT1遺伝子. 日本神経精神薬理学雑誌 30: 197-200.
  43. 橋本謙二、Serretti, A., 古瀬 勉(2010)座談会. 高齢者のうつ病に対する薬物療法-シグマ-1受容体アゴニストとしてのfluvoxamineの可能性. 臨床精神薬理 13: 2207-2217.
  44. 橋本謙二(2010)うつ病のバイオマーカー.Medical Bio. 7: 52-57.
  45. 橋本謙二(2010)神経可塑性と抗精神病作用としてのシグマ受容体の役割. 日本神経精神薬理学雑誌 30 (3): 123-127.
  46. 古瀬 勉、橋本謙二(2010)海外文献紹介:精神病性うつ病に対するFluvoxamine単剤療法:シグマ-1受容体の役割. 臨床精神薬理 13: 1461-1463.
  47. 中村 純、Stahl, S.M., 橋本謙二(2010)座談会. 精神疾患におけるシグマ-1受容体の役割とフルボキサミンの新たな可能性. 臨床精神薬理 13: 865-875.

2009年

  1. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: A potential role of sigma-1 receptors. Ann. Gen. Psychiatry. 2009 Dec. 21; 8(1): 26. [PubMed]
  2. Hashimoto K. Sigma-1 receptor: A novel therapeutic target for neuropsychiatric diseases. J. Brain Sci. 2009; 35: 7-12.
  3. Hattori E, Toyota T, Ishitsuka Y, Iwayama Y, Yamada K, Ujike H, Morita Y, Kodama M, Nakata K, Minabe Y, Nakamura K, Iwata Y, Takei N, Mori N, Naitoh H, Yamanouchi Y, Iwata N, Ozaki N, Kato T, Nishikawa T, Kashiwa A, Suzuki M, Shioe K, Shinohara M, Hirano M, Nanko S, Akahane A, Ueno M, Kaneko N, Watanabe Y, Someya T, Hashimoto K, Iyo M, Itokawa M, Arai M, Nankai M, Inada T, Yoshida S, Kunugi H, Nakamura M, Iijima Y, Okazaki Y, Higuchi T, Yoshikawa T. Preliminary genome-wide association study of bipolar disorder in the Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009 Dec 5;150B: 1110-1117.[PubMed]
  4. Hashimoto K. Can sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol. Disord. Drug Targets. 2009 Dec 1; 8 (6): 470-474. [PubMed]
  5. Hagiwara H, Iyo M, Hashimoto K. Mithramycin protects dopaminergic neurotoxicity in mouse brain after administration of methamphetamine. Brain Res. 2009 Dec 8; 1301: 189-196. [PubMed]
  6. Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M, Hashimoto K. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of adrenergic a1 receptors. Eur. Neuropsychopharmacol. 2009 Dec; 19 (12): 861-867. [PubMed]
  7. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009 Oct; 61 (2): 105-123.[PubMed]
  8. Hashimoto K. BDNF and obesity in the WAGR syndrome. Clin. Psychopharmacol. Neurosci. 2009 Aug; 7 (2): 63.
  9. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents Med. Chem. 2009 Sep; 9 (3): 197-204. [PubMed]
  10. Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in human brain after single oral administration of donepezil: A positron emission tomography study using [11]SA4503. Int. J. Neuropsychopharmacol. 2009 Sep; 12 (8): 1127-1131. [PubMed]
  11. Matsuzawa D, Shirayama Y, Shimizu E, Hashimoto K, Iyo M. Evaluating the cognitive decline in early-stage frontotemporal dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 Aug 31; 33 (3): 1077-1079. [PubMed]
  12. Hashimoto K. Comments to “An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder”. J. Clin. Psychopharmacol. 2009 August; 29 (4): 411-412.[PubMed]
  13. Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 2009 July 7; 279: 189-193. [PubMed]
  14. Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, Tsukamoto T. Co-administration of D-amino acid oxidase inhibitor potentiates the efficacy of D-serine on prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry 2009 June 15; 65 (12): 1103-1106. [PubMed]
  15. Nakazato M, Tchanturia K, Schmidt U, Campbell IV, Treasure J, Collier DA, Hashimoto K, Iyo M. Brain-derived neurotrophic factor (BDNF) and set-shifting in currently ill and recovered anorexia nervosa (AN) patients. Psychological. Med. 2009 June; 36 (9): 1029-1035. [PubMed]
  16. Toyohara J, Sakata M, Wu J, Ishikawa M, Oda K, Ishii K, Iyo M, Hashimoto K, Ishiwata K. Preclinical and the first clinical studies on [11]CHIBA-1001 for mapping a7 nicotinic receptors by positron emission tomography. Ann. Nucl. Med. 2009 May; 23 (3): 301-309. [PubMed]
  17. Hashimoto K. Sarcosine and lower risk of prostate cancer in male patients with schizophrenia. Open Clin. Chem. J. 2009; 2: 22-23. [PDF]
  18. Hashimoto K. Nausea associated with a nicotinic agonist therapy in schizophrenia. Clin. Psychopharmacol. Neurosci. 2009 February; 7 (1): 26-27.
  19. Horio M, Fujita Y, Ishima T, Iyo M, Ferraris D, Tsukamoto T, Hashimoto K. Effects of D-amino acid oxidase inhibitor on the extracellular D-alanine levels and the efficacy of D-alanine on dizocilpine-induced prepulse inhibition deficits in mice. Open Clin. Chem. J. 2009; 2: 16-21. [PDF]
  20. Ohgake S, Shimizu E, Hashimoto K, Okamura N, Koike K, Koizumi H, Fujisaki M, Kanahara N, Matsuda S, Sutoh C, Matsuzawa D, Muramatsu H, Muramatsu T, Iyo M. Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 April 30; 33 (3): 541-546.
  21. Takizawa R, Hashimoto K, Tochigi M, Kawakubo Y, Marumo K, Sasaki T, Fukuda M, Kasai K. Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 April 30; 33 (3): 491-498.
  22. Kanahara N, Shimizu E, Sekine Y, Uchida Y, Shibuya T, Yamanaka H, Hashimoto T, Asaka T, Sasaki T, Miyatake R, Ohkamia T, Fukami G, Fujisaki M, Watanabe H, Shirayama Y, Hayashi H, Hashimoto K, Asano M, Iyo M. Does hypofrontality expand to global brain area in progression of schizophrenia? : A cross-sectional study between first-episode and chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 April 30; 33 (3): 410-415.
  23. Matsuoka Y, Nishi D, Nakajima S, Yonemoto N, Hashimoto K, Noguchi H, Otomo Y, Kim Y. The Tachikawa cohort of motor vehicle accident study: design, methods, and cohort profiles. Soc. Psychiatry Psychiatr. Epidemiol. 2009 April; 44: 333-340. [PubMed]
  24. Kanahara N, Iyo M, Hashimoto K. Failure to confirm the association between the PIK4CA gene and schizophrenia in a Japanese population. Am. J. Med. Genet. Part B. 2009 April 5; 150B: 450-452. [PubMed]
  25. Kanahara N, Miyatake R, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M, Hashimoto, K. Association study between the PIK4CA gene and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. Part B. 2009 March 5; 150B (2): 233-238. [PubMed]
  26. Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu M, Minase T, Tanibuchi Y, Hagiwara H, Iyo M, Hashimoto K. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin. Chem. J. 2009; 2: 7-11. [PDF]
  27. Hashimoto K. Reply to: Minocycline, schizophrenia and GluR1 glutamate receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 Feb. 1; 33(1): 167. [PubMed]
  28. Matsuzawa D, Hashimoto K, Hashimoto T, Shimizu E, Watanabe H, Fujita Y, Iyo M. Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. Am. J. Med. Genet. Part B. 2009 January 5; 150B (1): 86-94. [PubMed]
  29. 橋本謙二、伊豫雅臣(2009)薬物依存症の脳画像研究と新しい治療法.医学のあゆみ 231 (10): 1079-1082.
  30. 橋本謙二、三村 将(2009)シグマ受容体リガンドとしてのFluvoxamineの臨床的有用性を考える.Progress in Medicine 29 (9): 2229-2234.
  31. 橋本謙二、林 輝男(2009)うつ病をはじめとする精神疾患におけるシグマ-1受容体アゴニストの役割と抗うつ薬の新たな可能性. 臨床精神薬理 12: 2067-2074.
  32. 橋本謙二(2009)脳由来神経栄養因子とうつ病. 脳と精神の医学 20 (1): 55-60.
  33. 橋本謙二、Joseph Zohar、福田正人(2009)座談会. 強迫性障害に対する薬物療法-シグマ受容体を介したSSRIの新たな可能性-. 臨床精神薬理 12: 781-790.
  34. 橋本謙二(2009)「身体表現性障害に対するSSRIの有用性について-fluvoxamineを用いて」の論文に対するコメント.臨床精神薬理 12 (3): 521-522.
  35. 橋本謙二(2009) CINP 2008 Satellite Symposium [うつ病治療におけるシグマ1受容体とその臨床意義]. シグマ-1受容体に関する基礎的および臨床的知見. 臨床精神薬理 12 (2): 355-361.
  36. 石川雅智、石渡喜一、石井賢二、木村裕一、坂田宗之、長縄美香、織田圭一、宮武良輔、藤崎美久、清水栄司、白山幸彦、伊豫雅臣、橋本謙二(2009)海外文献紹介:Fluvoxamine単回経口投与後のヒト脳におけるシグマ-1受容体占拠率:[11C]SA4503を用いたポジトロン断層撮影研究. 臨床精神薬理 12 (1): 177-186.

2008年

  1. Inoue R, Hashimoto K, Harai T, Mori H. NMDA- and beta-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J. Neurosci. 2008 Dec 31;28(53):14486-91. [PubMed]
  2. Iwata Y, Tsuchiya KJ, Mikawa S, Nakamura K, Takai Y, Suda S, Sekine Y, Suzuki K, Kawai M, Sugihara G, Matsuzaki H, Hashimoto K, Tsujii M, Sugiyama T, Takei N, Mori N. Serum levels of P-selectin in patients with high-functioning autism. Bri. J. Psychiatry 2008 Oct; 193(4); 338-339. [PubMed]
  3. Hashimoto K. Correspondence: Regarding “N-Acetyl cysteine as a glutathione precursor for schizophrenia ? a double-blind, randomized, placebo-controlled trial”. Biol. Psychiatry 2008 Nov. 1; 64 (9): e1. [PubMed]
  4. Hashimoto T, Hashimoto K, Miyatake R, Matsuzawa D, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M. Association study between polymorphisms in glutathione-related genes and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. Part B. 2008 Oct 5; 147B(7):1040-1046. [PubMed]
  5. Hashimoto K. Correspondence: Food addictives and hyperactive behaviors in children. Clin. Psychopharmacol. Neurosci. 2008 August; 6 (2): 79.
  6. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 Oct 1; 32: 1758-1759. [PubMed]
  7. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 Oct. 1; 32; 1656-1659. [PubMed]
  8. Hashimoto K, Nishiyama S, Ohba H, Matsuo M, Kobashi T, Takahagi M, Iyo M, Kitashoji T, Tsukada H. [11C]CHIBA-1001 as a novel PET ligand for α7 nicotinic receptors in the brain: A PET study in conscious monkeys. PLoS ONE 2008 Sept. 18; 3 (9): e3231. [PubMed]
  9. Hashimoto K. CSF serine enantiomers and glycine in the study of neurologic and psychiatric disorders. Clin. Chemistry 2008 Sept; 54(9): 1413-1414. [PubMed]
  10. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 2008 July 2; 3(7): e2558.[PubMed]
  11. Ferraris D, Duvall B, Ko YS, Thomas AG, Rojas C, Majer P, Hashimoto K, Tsukamoto T. Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J. Med. Chem. 2008 June 26; 51(12): 3357-3359. [PubMed]
  12. Fujita Y, Ishima T, Horio M, Hagiwara H, Iyo M, Hashimoto K. Alterations in plasma levels of amino acids after intracerebroventricular administration of L-serine or D-serine in conscious and freely moving rats. The Open. Clin. Chem. J. 2008 June; 1: 22-26. [PFD]
  13. Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T, Matsuzawa D, Shirayama Y, Hashimoto K, Iyo, M. Glycine and D-serine, but not D-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology 2008 June; 198(3): 363-374.
  14. Iwata Y, Suzuki K, Wakuda T, Seki N, Thanseem I, Matsuzaki H, Mamiya T, Ueki T, Mikawa S, Sasaki T, Suda S, Yamamoto S, Tsuchiya KJ, Sugihara G, Nakamura K, Sato K, Takei N, Hashimoto K, Mori N. Irradiation at adulthood as a new model of schizophrenia. PLoS ONE 2008 May 28; 3(5): e2283.
  15. Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 May 15; 32 (4): 1072-1073.[PubMed]
  16. Hikida T, Mustafa AK, Maeda K, Fujii K, Barrow RK, Saleh M, Oby L, Huganir RL, Snyder SH, Hashimoto K, Sawa A. Modulation of D-serine levels in brains of mice lacking PICK1. Biol. Psychiatry 2008 May 15; 63 (10): 997-1000.[PubMed]
  17. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor. Eur. Neuropsychopharmacology 2008 June; 18 (6): 448-454.[PubMed]
  18. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine. Eur. Neuropsychopharmacology 2008 June; 18 (6): 414-421.[PubMed]
  19. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K. Negative correlation between brain glutathione levels and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 2008 April; 4 (3): e1944.[PubMed]
  20. Hashimoto K, Shinohe A, Mori N. Reply to: Hyperglutamatergic hypothesis of autism. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 April; 32(3): 912-913.[PubMed]
  21. Sakata M, Kimura Y, Naganawa M, Ishikawa M, Oda K, Ishii K, Hashimoto K, Chihara K, Ishiwata K. Shortened protocol in practical [11C]SA4503-PET studies for sigma-1 receptor quantification. Ann. Nucl. Med. 2008 Feb; 22(2): 143-146. [PubMed]
  22. Takeshita M, Yamada K, Hattori E, Iwayama Y, Toyota T, Iwata Y, Tsuchiya KJ, Sugihara G, Hashimoto K, Watanabe H, Iyo M, Kikuchi M, Okazaki Y, Yoshikawa T. Genetic examination of the PLXNA2 gene in Japanese and Chinese schizophrenics. Schizophrenia. Res. 2008 Feb; 99(1-3): 359-364.[PubMed]
  23. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 Feb 15; 32 (2): 336-339.[PubMed]
  24. Hashimoto T, Shimizu E, Koike K, Orita Y, Suzuki T, Kanahara N, Fukami G, Miyatake R, Shinoda N, Fujisaki M, Shirayama Y, Hashimoto K, Iyo M. Deficits in auditory P50 inhibition in obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 Jan 1; 32 (1): 288-296.[PubMed]
  25. Suzuki K, Nakamura K, Iwata Y, Sekine Y, Kawai M, Sugihara G, Tsuchiya KJ, Suda S, Matsuzaki H, Takei N, Hashimoto K, Mori N. Decreased expression for the reelin receptor VLDLR in peripheral lymphocytes of drug naive schizophrenic patients. Schizophrenia Res. 2008 January; 98 (1-3): 148-156.[PubMed]
  26. Karasawa J, Hashimoto K, Chaki S. D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res. 2008 Jan 10; 186 (1): 78-83.[PubMed]
  27. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective a7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 2008 Jan 1; 63(1): 92-97.[PubMed]
  28. 橋本謙二(2008)覚せい剤関連精神障害の治療薬としてのミノサイクリン. 日本神経精神薬理学雑誌 28:19-22.
  29. 萩原裕子、橋本謙二(2008)末梢血因子を用いた精神疾患診断法の進歩-薬物依存症における脳-末梢関連に関する最新知見. 日本アルコール・薬物医学会雑誌 43:77-86.
  30. 橋本謙二、Ian Hindmarch, 笠井清登(2008)うつ病・不安障害治療とシグマ受容体.臨床精神薬理 11: 1407-1417.
  31. 橋本謙二(2008)今後期待される抗精神病薬と、その作用メカニズム. こころの臨床アラカルト 27: 469-472.
  32. 橋本謙二(2008)仮説の矛盾点. こころの臨床アラカルト 27: 484-488.

2007年

  1. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007 Dec 1; 25 (11): 1310-1316.[PubMed]
  2. Watanabe A, Toyota T, Owada Y, Hayashi T, Owayama Y, Matsumata M, Ishitsuka Y, Nakaya A, Maekawa M, Ohnishi T, Arai R, Sakurai K, Yamada K, Kondo H, Hashimoto K, Osumi N, Yoshikawa T. Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol. 2007 Nov 13; 5(11): e297.[PubMed]
  3. Tsuchiya K, Hashimoto K, Iwata Y, Tsujii M, Sekine Y, Sugihara G, Matsuzaki H, Suda S, Kawai M, Nakamura K, Minabe Y, Yagi A, Iyo M, Takei N., Mori N. Decreased serum levels of PECAM-1 in subjects with high-functioning autism: a negative correlation with head circumference at birth. Biol Psychiatry. 2007 Nov. 1; 62 (9): 1056-1058.[PubMed]
  4. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: A PET study using [11C]SA4503. Biol Psychiatry. 2007 Oct 15; 62(8): 878-883.[PubMed]
  5. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S, Reinscheid RK. Gender-specific association of a functional coding polymorphism in the neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1; 31(7): 1444-1448.[PubMed]
  6. Hashimoto K. Glycine transporter-1 inhibitors as novel therapeutic drugs for schizophrenia. CNS Agents Med Chem. 2007 September; 7 (3): 177-182.
  7. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007 Sept; 32 (9): 2001-2010. [PubMed]
  8. Suzuki K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suda S, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Takei N, Mori N. Decreased serum levels of epidermal growth factor in adult patients with high-functioning autism. Biol Psychiatry. 2007 Aug 1; 62(3): 267-269.[PubMed]
  9. Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, Maeda K, Suzuki Y, Mashimo Y, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Hata A, Sawa A, Iyo M. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007 Jul; 164(7): 1105-1114.[PubMed]
  10. Matsuzaki H, Minabe Y, Nakamura K, Suzuki K, Iwata Y, Sekine Y, Tsuchiya KJ, Sugihara G, Suda S, Takei N, Nakahara D, Hashimoto K, Nairn AC, Mori N, Sato K. Disruption of Reelin signaling attenuates methamphetamine-induced hyperlocomotion. Eur J Neurosci. 2007 Jun; 25(11): 3376-3384.[PubMed]
  11. Tomiya M, Fukushima T, Watanabe H, Fukami G, Fujisaki M, Iyo M, Hashimoto K, Mitsuhashi S., Toyo'oka T. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin Chim Acta. 2007 May; 380(1-2):186-190.[PubMed]
  12. Fukushima T, Mitsuhashi S, Tomiya M, Kawai J, Hashimoto K, Toyo'oka T. Determination of rat brain kynurenic acid by column-switching HPLC with fluorescence detection. Biomed Chromatogr. 2007 May; 21(5): 514-519.[PubMed]
  13. Shimizu E, Imai M, Fujisaki M, Shinoda N, Handa S, Watanabe H, Nakazato M, Hashimoto K, Iyo M. Maintenance electroconvulsive therapy (ECT) for treatment-resistant disorganized schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30; 31(2):571-573.[PubMed]
  14. Sugihara G, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Takei N, Mori N. Decreased serum levels of hepatocyte growth factor in adult patients with autism. Prog Neuropharmacol Biol Psychiatry. 2007 Mar 30; 31(2):412-415.[PubMed]
  15. Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A PET study in conscious monkeys. Biol Psychiatry. 2007 Mar 1; 61(5):577-581.[PubMed]
  16. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007 Mar; 32(3):514-521.[PubMed]
  17. Hashimoto K. BDNF variant linked to anxiety-related behaviors. BioEssays 2007 Feb; 29(2): 116-119.[PubMed]
  18. Fukushima T, Mitsuhashi S, Tomiya M, Iyo M, Hashimoto K, Toyo'oka T. Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino acids. Clin Chim Acta. 2007 Feb; 377(1-2): 174-178.[PubMed]
  19. Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, Hashimoto K, Iyo M. Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30; 31:288-291.[PubMed]
  20. Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Takei N, Mori N. Decreased serum levels of transforming growth factor-b1 in adult patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007 Jan 30; 31:187-190.[PubMed]
  21. Nakajima M, Hattori E, Yamada K, Iwayama Y, Toyota T, Iwata Y, Tsuchiya KJ, Sugihara G, Hashimoto K, Watanabe H, Iyo M, Hoshika A, Yoshikawa T. Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics. J Hum Genet. 2007; 52(1): 86-91.[PubMed]
  22. Shimizu E, Hashimoto K, Ochi S, Fukami G, Fujisaki M, Koike K, Okamura N, Ohgake S, Koizumi H, Matsuzawa D, Zhang L, Watanabe H, Nakazato M, Shinoda N, Komatsu N, Morita F, Iyo M. Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J Psychiatr Res. 2007 Jan-Feb; 41(1-2): 49-56.[PubMed]
  23. 橋本謙二(2007)認知機能障害の治療薬開発の現状. 臨床精神薬理 10:1193-1198.
  24. 橋本謙二(2007)精神疾患におけるシグマ受容体の役割-特集にあたって. 臨床精神薬理 10:1203-1204.
  25. 石川雅智、橋本謙二、伊豫雅臣(2007)PETによるシグマ-1受容体測定の意義. 臨床精神薬理 10:1229-1236.
  26. 橋本謙二(2007)統合失調症の認知機能障害および精神病性うつ病におけるシグマ-1受容体の役割. 臨床精神薬理 10:1243-1248.
  27. 橋本謙二(2007)薬物依存の脳画像解析と臨床遺伝学的研究.分子精神医学 7: 245-248.
  28. 工藤佳久、小泉修一、和田圭司、橋本謙二(2007)グリア細胞を標的とした医薬品の創製.日薬理誌 130: 185-192.
  29. 岩田泰秀、松崎秀夫、須田史朗、鈴木勝昭、中村和彦、橋本謙二、森則夫(2007)自閉症の抹消生物学的マーカーの検索.脳21 10: 261-266.

2006年

  1. Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: Role of a7 nicotinic receptors. Eur J Pharmacol. 2006 Dec 28; 553(1-3): 191-195.[PubMed]
  2. Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suzuki K, Minabe Y, Takei N, Iyo M, Mori N. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropharmacol Biol Psychiatry. 2006 Dec 30; 30(8): 1529-1531.[PubMed]
  3. Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Iyo M, Takei N, Mori N. Increased serum levels of glutamate in adult patients with autism. Prog Neuropharmacol Biol Psychiatry. 2006 Dec 30; 30(8): 1472-1477.[PubMed]
  4. Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, Iyo M, Hashimoto K. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropharmacol Biol Psychiatry. 2006 Dec 30; 30(8): 1381-1393.[PubMed]
  5. Koizumi H, Hashimoto K, Iyo M. Dietary restriction changes behaviors in brain-derived neurotrophic factor heterozygous mice: role of serotonergic system. Eur J Neurosci. 2006 Oct; 24(8): 2335-2344.[PubMed]
  6. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci. 2006 Aug; 4 (1): 3-10.
  7. Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol. 2006 Aug 21; 544(1-3): 1-9. [PubMed]
  8. Nakazato M, Hashimoto K, Yoshimura K, Hashimoto T, Shimizu E, Iyo M. No change between the serum brain-derived neurotrophic factor in female patients with anorexia nervosa before and after partial weight recovery. Prog Neuropharmacol Biol Psychiatry. 2006 Aug; 30(6): 1117-1121.[PubMed]
  9. Tatsumi R, Fujio M, Takanashi S, Numata A, Katayama J, Satoh H, Shiigi Y, Maeda J, Kuriyama M, Horikawa T, Murozono T, Hashimoto K, Tanaka, H. (R)-3’-(3-Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5’-oxazolidin]-2’-one, a novel and potent a7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J Med Chem. 2006 Jul 13; 49(14): 4374-4383.[PubMed]
  10. Hashimoto K, Ishiwata K. Sigma receptor ligands: Possible applications as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006; 12(30): 3857-3876.[PubMed]
  11. Hayashi Y, Ishibashi H, Hashimoto K, Nakanishi H. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia. 2006 Apr 15; 53(6): 660-668.[PubMed]
  12. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006 Mar 15; 59(6): 546-554.[PubMed]
  13. Iwayama Y, Hashimoto K, Nakajima M, Toyota T, Yamada K, Shimizu E, Itokawa M, Hoshika A, Iyo M, Yoshikawa T. Analysis of correlation between serum D-serine levels and functional promoter polymorphisms of GRIN2A and GRIN2B genes. Neurosci Lett. 2006 Feb 13; 394(2): 101-104.[PubMed]
  14. Shimizu E, Hashimoto K, Ohgake S, Koizumi H, Okamura N, Koike K, Fujisaki M, Iyo M. Association between angiotensin I-converting enzyme insertion/deletion gene functional polymorphism and novelty seeking personality in healthy females. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan; 30(1): 99-103.[PubMed]
  15. Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents on CNS Drug Discovery. 2006 Jan; 1: 43-53.[PubMed]
  16. 橋本謙二(2006)脳由来神経栄養因子(BDNF)とうつ病. 脳21 9: 14-18.
  17. 橋本謙二、伊豫雅臣(2006)グルタミン酸受容体拮抗薬の神経保護作用:mGluR GroupⅡ作動薬の神経保護作用.Clinical Neuroscience 24 (2): 197-199.
  18. 橋本謙二(2006)うつ病と脳由来神経栄養因子(BDNF). 日本薬理学雑誌 127: 201-204.
  19. 橋本謙二(2006)フルボキサミンの新規薬理作用としてのシグマ受容体.分子精神医学 6: 109-110.
  20. 橋本謙二(2006)統合失調症の認知機能障害治療薬としてのトロピセトロンの可能性. 臨床精神薬理 9:1439-1441.
  21. 橋本謙二(2006)社会不安障害の治療薬におけるシグマ-1受容体アゴニストの役割. 臨床精神薬理 9:1653-1660.
  22. 橋本謙二、藤田有子、伊豫雅臣(2006)Phencyclidine投与によるマウスの認知機能障害はfluvoxamineの亜慢性投与によって改善される:シグマ-1受容体の役割.臨床精神薬理 9:2359-2370.
  23. 橋本謙二(2006)精神神経疾患の新しい治療ターゲットとしてのニコチン受容体.日本アルコール精神医学雑誌 13:11-17.

2005年

  1. Hashimoto K. Neonatal signs following exposure to SSRIs. Hum Psychopharmacol. 2005 Nov; 20(7): 522.[PubMed]
  2. Hashimoto K, Iyo M, Freedman R, Stevens KE. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of a7 nicotinic acetylcholine receptors. Psychopharmacology (Berl). 2005 Nov; 183(1): 13-19.[PubMed]
  3. Yamamoto T, Sakakibara R, Hashimoto K, Nakazawa K, Uchiyama T, Liu Z, Ito T, Hattori T. Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience. 2005; 135(1): 299-303.[PubMed]
  4. Hashimoto K, Fujita Y, Shimizu E, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol. 2005 Sep 5; 519(1-2): 114-117.[PubMed]
  5. Hashimoto K, Koike K, Shimizu E, Iyo M. a7 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr Med Chem-CNS Agents. 2005 September; 5: 171-184.
  6. Hashimoto K, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Takei N, Iyo M. No changes in serum epidermal growth factor levels in patients with schizophrenia. Psychiatry Res. 2005 June 30; 135: 257-260.[PubMed]
  7. Ohgake S, Hashimoto K, Shimizu E, Koizumi H, Okamura N, Koike K, Matsuzawa D, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Shirayama Y, Iyo M. Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addiction Biol. 2005 June; 10(2): 145-148.[PubMed]
  8. Matsuzawa D, Hashimoto K, Shimizu E, Fujisaki M, Iyo M. Functional polymorphism of the glutathione peroxidase 1 gene is associated with personality traits in healthy subjects. Neuropsychobiology. 2005 June 29; 52: 68-70.[PubMed]
  9. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropharmacol Biol Psychiatry. 2005 June; 29: 767-769.[PubMed]
  10. Shimizu E, Hashimoto K, Itoh K, Kobayashi K, Mitsumori M, Koizumi H, Ohgake S, Okamura N, Koike K, Matsuzawa D, Kumakiri C, Nakazato M, Komatsu N, Iyo M. No association of the brain-derived neurotrophic factor (BDNF) gene polymorphisms with panic disorder. Prog Neuropharmacol Biol Psychiatry. 2005 June; 29: 708-712.[PubMed]
  11. Kobayashi K, Shimizu E, Hashimoto K, Mitsumori M, Koike K, Okamura N, Koizumi H, Ohgake S, Matsuzawa D, Zhang L, Nakazato M, Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005 June; 29: 658-663.[PubMed]
  12. Yamada K*, Ohnishi T*, Hashimoto K*, Ohba H, Iwayama-Shigeno Y, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry. 2005 June 15; 57(12): 1493-1503 (*equal contribution).[PubMed]
  13. Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, Nakazato M, Okamura N, Stevens KE, Freedman R, Iyo M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophrenia Res. 2005 Jul 1;76(1):67-72.[PubMed]
  14. Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev. 2005 1(2): 151-163.
  15. Salama RH, Muramatsu H, Shimizu E, Hashimoto K, Ohgake S, Watanabe H, Komatsu N, Okamura N, Koike K, Shinoda N, Okada S, Iyo M, Muramatsu T. Increased midkine levels in sera from patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2005 May; 29(4): 611-6.[PubMed]
  16. Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M. Role of brain-derived neurotrophic factor in eating disorders: Recent findings and its pathophysiological implications. Prog Neuropsychopharmacol Biol Psychiatry. 2005 May; 29(4): 499-504.[PubMed]
  17. Tatsumi R, Fujio M, Satoh H, Katayama J, Takanashi S, Hashimoto K, Tanaka H. Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand. J Med Chem. 2005 Apr 7; 48(7): 2678-86.[PubMed]
  18. Koizumi H, Hashimoto K, Shimizu E, Iyo M, Mashimo Y, Hata A. Further analysis of microsatellite marker in the BDNF gene. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 23; 135B(1): 103.[PubMed]
  19. Hashimoto T, Hashimoto K, Matsuzawa D, Shimizu E, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 23; 135B(1): 5-9.[PubMed]
  20. Koike K, Hashimoto K, Fukami G, Okamura N, Zhang L, Ohgake S, Koizumi H, Matsuzawa D, Kawamura N, Shimizu E, Iyo M. The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Neuropharmacology. 2005 Mar; 48(3): 391-7.[PubMed]
  21. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom L, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry. 2005 Jan 31; 5(1): 6 [PubMed]
  22. Okamoto H, Shimizu E, Ozawa K, Hashimoto K, Iyo M. Lithium augmentation in milnacipran-refractory depression for the prevention of relapse following electroconvulsive therapy. Aust N Z J Psychiatry. 2005 Jan; 39(1-2): 108.[PubMed]
  23. Itoh K, Hashimoto K, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Iwata N, Komiyama T, Yamada M, Sora I, Nakata K, Ujike H, Iyo M. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet. 2005 Jan; 132B(1): 70-73.[PubMed]
  24. 橋本謙二(2005)脳由来神経栄養因子(BDNF). 心身医学 9(1): 30-34.
  25. 橋本謙二(2005)SSRIの作用機序に関する最新の知見. トラウマチック・ストレス 3:77-81.
  26. 橋本謙二(2005)うつ病および不安障害におけるシグマ受容体の役割. 臨床精神薬理 8:1623-1629.
  27. 橋本謙二(2005)統合失調症の治療薬と分子医学. 細胞 37:569-572.

Page Top